Top Markets
Coin of the day
Lakewood-Amedex Biotherapeutics Inc. Common Stock Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT
Rank in Stocks #35448
This biopharmaceutical company is dedicated to developing innovative... This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.
Share Price
$2.23
Last synced: 2026-08-14
Market Cap
$3.90M
Change (1 day)
-4.48%
Change (1 year)
-
Country
US
Trade Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)

Category

Revenue for Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)
Revenue in Aug 2026 TTM: 0
According to Lakewood-Amedex Biotherapeutics Inc. Common Stock latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Lakewood-Amedex Biotherapeutics Inc. Common Stock from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE